Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity
Author:
Publisher
Elsevier BV
Subject
Urology
Reference114 articles.
1. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration;Liberati;Ann Intern Med,2009
2. Grawitz tumor of kidney;Jellinek;Cal State J Med,1904
3. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance;Shuch;BJU Int,2011
4. On hypernephromas of the kidney;Kelly;Philadelphia Med J,1898
5. Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis;Kovacs;J Natl Cancer Inst,1989
Cited by 423 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Molecular biology, genetic, and epigenetics of kidney tumor;Genetics and Epigenetics of Genitourinary Diseases;2025
2. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma;Journal of Chemotherapy;2024-09-10
3. VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING;2024-09-06
4. Evaluating trophinin associated protein as a biomarker of prognosis and therapy response in renal cell carcinoma;BMC Cancer;2024-08-17
5. FOXC1 transcriptionally suppresses ABHD5 to inhibit the progression of renal cell carcinoma through AMPK/mTOR pathway;Cell Biology and Toxicology;2024-08-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3